The present invention provides an aqueous solution evaporative treatment method that makes it possible to efficiently perform evaporative treatment of an aqueous solution containing calcium, magnesium, and silica. The aqueous solution evaporative treatment method comprises a seed crystal mixing step of adding to and mixing with an aqueous solution containing calcium, magnesium, and silica at least any one of magnesium salt and silicate together with calcium salt as seed crystals, and an evaporative concentration step of evaporatively concentrating the aqueous solution together with the seed crystals.

The present disclosure relates to a wastewater flue evaporating device. An wastewater evaporation crystallizer is provided, including an evaporating tube inlet, an inlet flange, an inlet chamber, a pneumatic inlet baffle, an evaporating tube body, a pneumatic outlet baffle, an outlet chamber, an outlet flange, and an evaporating tube outlet which are successively coupled, where the evaporating tube inlet is connected to provide a gas pipeline; the gas pipeline is connected on a flue between an external denitration device and an air preheater; the evaporating tube outlet is communicated with an inlet flue of a dust collector; the evaporating tube body is provided with a wastewater nozzle; and the wastewater nozzle is communicated with a pretreated waste pipe. The present disclosure provides an efficient and energy-saving wastewater evaporation crystallizer which increases evaporation efficiency by bringing in a high-temperature gas at a front end of the air preheater.

A method having the following steps: (1) providing a composition containing proteins and amino acids from mucous membranes of animals for slaughter, inorganic salts and water, wherein the sum of the mass of proteins and amino acids in the dry mass of said composition is 30 to 70 weight percent and the mass of inorganic salts in the dry mass of said composition is at least 7.5 weight percent; (2) filtering the composition to obtain a filtrate and a filter cake; (3) cooling the filtrate to a temperature in the range of 15? C. to 15? C. to form a precipitate; (4) separating the resulting precipitate to obtain the liquid phase as product. The disclosure further relates to the products of this method.

The present disclosure relates to a method for continuous preparation of high bulk density methionine crystals. The process of the method is as follows: a hydrolysate solution, which is obtained from a reaction of 5-(?-methylmercaptoethyl) hydantoin and a potassium carbonate solution, is mixed with an external circulation material from a DTB neutralization crystallizer having a gas phase neutralization section; after being cooled, the mixture enters a liquid distributor of a neutralization region in the upper part of the crystallizer and is sprayed in the form of liquid droplet or trickle into carbon dioxide gas for neutralization reaction, and then naturally falls into a crystallization region in the lower part to be mixed with a material in the region; the obtained mixture grows on fine crystals in a system to form crystals having larger particle diameters, and meanwhile new crystal nucleuses are formed; in a deposition area in the middle part of the crystallization region, the crystals having larger particle diameters deposits into an elutriation leg, while the fine crystals circulate with the external circulation material, and a part of the external circulation material is used to elutriate the crystals in the elutriation leg, while another part of the same is used to be mixed with the hydrolysate solution; and the crystals in the elutriation leg are separated, washed and dried to obtain the high bulk density methionine product.

The present disclosure relates to a wastewater flue evaporating device. An wastewater evaporation crystallizer is provided, including an evaporating tube inlet, an inlet flange, an inlet chamber, a pneumatic inlet baffle, an evaporating tube body, a pneumatic outlet baffle, an outlet chamber, an outlet flange, and an evaporating tube outlet which are successively coupled, where the evaporating tube inlet is connected to provide a gas pipeline; the gas pipeline is connected on a flue between an external denitration device and an air preheater; the evaporating tube outlet is communicated with an inlet flue of a dust collector; the evaporating tube body is provided with a wastewater nozzle; and the wastewater nozzle is communicated with a pretreated waste pipe. The present disclosure provides an efficient and energy-saving wastewater evaporation crystallizer which increases evaporation efficiency by bringing in a high-temperature gas at a front end of the air preheater.

A process and apparatus for enhanced boron removal from water. The process includes the steps of reacting potassium carbonate or ammonium carbonate with calcium borate in a stream of feed water to form a stream having calcium carbonate and potassium borate salt or ammonium borate salt. The stream having calcium carbonate and potassium borate or ammonium borate is introduced to an ion exchange vessel containing resin having methylglucamine in salt form with potassium carbonate or sodium carbonate to form borate and potassium sulfate or sodium sulfate. The resin in the ion exchange vessel is periodically regenerated.

The present invention relates to a process for the preparation of Trisodium (4-{[(1S.3R)-1-([1,1-biphenyl]-4-yl-methyl)-4-ethoxy-3-methyl-4-oxobutyl]amino}-4-oxo butanoate)-(N-pentanoyl-N-{[2-(1H-tetrazol-1-id-5-yl)[1,1-biphenyl]-4-yl]methyl}-L-valinate) represented by the following structural formula-1:

##STR00001##

A process for preparing (3R)-3-[2-Hydroxy(di-2-thienyl)acetoxy]-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidinium bromide) comprises reacting 2-hydroxy-2,2-dithien-2-ylacetic acid 1-azabicyclo[2.2.2]oct-3(R) yl methyl ester and 3-phenoxypropyl bromide, wherein the reaction takes place in a solvent or mixture of solvents selected from the group of amides and/or the group of solvents with a sulfoxide group. Also provided is a crystalline aclidinium bromide characterized by a powder XRPD pattern having peaks at 7.70.2 2, 10.40.2 2, 13.20.2 2, 13.80.2 2, 19.90.2 2, 20.30.2 2, 20.80.2 2, 24.20.2 2, 25.70.2 2, 26.10.2 2, 29.20.2 2, 30.80.2 2. A pharmaceutical composition comprises aclidinium bromide according to the invention and a pharmaceutically acceptable excipient.

A process for desalinating water is disclosed. The process comprises the steps of passing a feed stream of saline solution 2 in a first desalination step through a reverse osmosis membrane desalination plant 3 comprising at least one reverse osmosis desalination unit 4 to form a first product water stream 5 having a reduced salt concentration relative to that of the feed stream of saline solution 2 and a first byproduct stream 6 having an increased salt concentration relative to that of the feed stream of saline solution 2 characterized in that the first byproduct stream 6 is passed in a second desalination step through a falling film crystallization unit 7 to form a second product water stream 8 having a reduced salt concentration relative to that of the first byproduct stream 6 and a second byproduct stream 9 having an increased salt concentration relative to that of the first byproduct stream 6. The invention further relates to an apparatus 1 for carrying out said process. The present invention further relates also to the use of the process or apparatus 1 for the reduction of the volume of the first byproduct stream 6 of a reverse osmosis membrane desalination plant 3, preferably an in-land desalination plant 3, or in a device or plant or process for producing desalinated water, for salt production, for co-production of power and desalinated water, or for air conditioning.

A process for preparing (3R)-3-[2-Hydroxy(di-2-thienyl)acetoxy]-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidinium bromide) comprises reacting 2-hydroxy-2,2-dithien-2-ylacetic acid 1-azabicyclo[2.2.2]oct-3(R) yl methyl ester and 3-phenoxypropyl bromide, wherein the reaction takes place in a solvent or mixture of solvents selected from the group of amides and/or the group of solvents with a sulfoxide group. Also provided is a crystalline aclidinium bromide characterized by a powder XRPD pattern having peaks at 7.70.2 2, 10.40.2 2, 13.20.2 2, 13.80.2 2, 19.90.2 2, 20.30.2 2, 20.80.2 2, 24.20.2 2, 25.70.2 2, 26.10.2 2, 29.20.2 2, 30.80.2 2. A pharmaceutical composition comprises aclidinium bromide according to the invention and a pharmaceutically acceptable excipient.